Erythrocyte Patents (Class 424/533)
  • Patent number: 11241457
    Abstract: The disclosure provides a composition comprising red cell-derived microparticles (RMPs) demonstrating acetylcholine esterase (AchE) activity of less than 350 pmol/min/106 particles/uL. The disclosure further provides a method of treating excessive bleeding comprising administering the composition to a subject.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: February 8, 2022
    Assignee: RxMP Therapeutics, Inc.
    Inventors: Yeon S. Ahn, Wenche Jy, Lawrence L. Horstman, Rifat Pamukcu
  • Patent number: 10273444
    Abstract: A lysis/resealing process for preparing erythrocytes containing active ingredient is provided comprising placing a globular concentrate in suspension in an isotonic solution having a haematocrit level which is equal to or greater than 65%, with refrigeration at 1 to 8° C.; measuring the osmotic fragility based on a sample of erythrocytes from that same globular concentrate, preferably on a sample of the suspension; lysis and internalization procedure of the active ingredient, inside the same chamber, at a temperature maintained at 1 to 8° C., comprising allowing the erythrocyte suspension having a haematocrit level equal to or greater than 65% and a hypotonic lysis solution which is refrigerated at 1 to 8° C., to circulate in a dialysis cartridge; the lysis parameters being adjusted in accordance with the osmotic fragility previously measured; and resealing in a second chamber at a temperature of from 30 to 40° C. by means of a hypertonic solution.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: April 30, 2019
    Assignee: ERYTECH PHARMA
    Inventor: Yann Godfrin
  • Patent number: 9102918
    Abstract: Methods and a system for transfusing blood to a mammalian subject. The method includes obtaining a volume of donated red blood cells (RBCs), adding an enhancement composition to the RBCs to form a treated blood composition, incubating the treated blood composition to form an incubated blood composition, and administering the incubated blood composition to a patient. The system includes a functionally-closed, sterile Y-type tube set.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: August 11, 2015
    Assignee: Biomet Biologics, LLC
    Inventor: Alan Gray
  • Patent number: 8759315
    Abstract: A ribose-related compound is added to whole blood or packed red cells which have suboptimal function as measured by decreased levels of 2,3-DPG in order to rejuvenate the red blood cells to normal function as seen by raised levels of 2,3-DPG. Two representative ribose-related compounds are D-ribose and inosine.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: June 24, 2014
    Assignee: Viacell, LLC
    Inventors: John A St. Cyr, Daniel G Ericson, Clarence A Johnson
  • Patent number: 8741640
    Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: June 3, 2014
    Inventors: Hong Gao, Zhenglun Zhu
  • Patent number: 8734854
    Abstract: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 27, 2014
    Inventors: James B. Gandy, Robert J. Brandt, Ryan N. Brandt, Clark Galen, Joseph F. Greco, John Kiwczak
  • Patent number: 8734787
    Abstract: Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: May 27, 2014
    Assignee: Erydel S.p.A.
    Inventors: Mauro Magnani, Luigia Rossi, Sara Biagiotti, Marzia Bianchi
  • Patent number: 8673293
    Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: March 18, 2014
    Assignee: Universitat Zurich
    Inventors: Roland Martin, Andreas Lutterotti, Stephen Miller
  • Publication number: 20130316011
    Abstract: Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.
    Type: Application
    Filed: January 27, 2012
    Publication date: November 28, 2013
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Yeon S. Ahn, Lawrence L. Horstman, Wenche Jy
  • Publication number: 20130101639
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Application
    Filed: October 17, 2012
    Publication date: April 25, 2013
    Applicant: SEARETE LLC
    Inventor: Searete LLC
  • Patent number: 8268362
    Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: September 18, 2012
    Assignee: Bio-Products & Bio-Engineering Aktiengesellschaft
    Inventors: Friedrich Braun, Hans Peter Spängler, Johann Eibl
  • Publication number: 20120027867
    Abstract: The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.
    Type: Application
    Filed: April 6, 2010
    Publication date: February 2, 2012
    Applicant: ENTEGRION, INC.
    Inventors: Thomas H. Fischer, Joseph A. DaCorta, Michael Lawrence Galiger
  • Patent number: 8105632
    Abstract: Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: January 31, 2012
    Assignee: University of Miami
    Inventors: Wenche Jy, Joaquin J. Jimenez, Lawrence L. Horstmann, Yeon S. Ahn, Eugene Ahn
  • Publication number: 20100323029
    Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 23, 2010
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
  • Patent number: 7687468
    Abstract: D-Ribose, a buffer and an anticoagulant are added to whole blood or packed red cells to extend function in storage beyond 42 days. Methods are disclosed to rejuvenate suboptimally functional red cells. The methods are comprised of incubation of the cells at 37° C. for 10 to 60 minutes in the presence of D-ribose.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: March 30, 2010
    Assignee: Viacell, LLC.
    Inventors: John A. St. Cyr, Daniel G. Ericson, Clarence A. Johnson
  • Publication number: 20090155376
    Abstract: The present invention provides compositions (blood sugar increase inhibitors) that have an action of lowering the blood sugar level of a subject in a hyperglycemic condition and are for use in lowering the blood sugar level of such a subject. Moreover, the present invention provides compositions for use in preventing or treating diseases resulting from hyperglycemia, in particular, diabetes and diabetic complications, due to the aforementioned action (a preventive or ameliorative composition for diseases resulting from hyperglycemia, an antidiabetic agent).
    Type: Application
    Filed: November 15, 2005
    Publication date: June 18, 2009
    Applicant: MG PHARMA INC.
    Inventors: Kyoichi Kagawa, Toshihiko Naruse, Chizuko Fukuhama
  • Patent number: 7521417
    Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: April 21, 2009
    Assignee: Northfield Laboratories, Inc.
    Inventors: Richard E. DeWoskin, Marc D. Doubleday
  • Patent number: 7411044
    Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: August 12, 2008
    Assignee: Northfield Laboratories, Inc.
    Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
  • Patent number: 7291592
    Abstract: Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: November 6, 2007
    Assignee: Northfield Laboratories, Inc.
    Inventors: Steven Gould, Richard DeWoskin, Marc Doubleday, George Hides
  • Patent number: 7267817
    Abstract: A method of treatment of a patient includes administering to the patient stored red blood cells and a hemoglobin solution. The stored red blood cells and the hemoglobin solution can be administered to the patient simultaneously. Alternatively, the hemoglobin solution can be administered to the patient prior to administrating the stored red blood cells or the stored red blood cells can be administered to the patient prior to administering the hemoglobin solution. A composition of the invention includes stored red blood cells and a hemoglobin solution.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: September 11, 2007
    Assignee: Biopure Corporation
    Inventors: Thomas C. Page, William R. Light, Edward E. Jacobs, Jr.
  • Patent number: 7169547
    Abstract: A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 30, 2007
    Assignee: New York Blood Center, Inc.
    Inventors: Pablo Rubinstein, Philip Henry Coelho, Cladd E. Stevens
  • Patent number: 7166278
    Abstract: It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an ?-galactosyl (Gal) epitope, for example, Gal?(1->3)Gal?(1->4)GlcNac (linear B type 2) or Gal?(1->3) Gal?(1->4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced, or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: January 23, 2007
    Assignee: RBC Biotechnology, Inc.
    Inventor: Alex Zhu
  • Patent number: 7135553
    Abstract: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: November 14, 2006
    Assignee: Northfield Laboratories, Inc.
    Inventors: Anthony Avella, Richard DeWoskin, Marc Doubleday
  • Patent number: 7094378
    Abstract: Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value; mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: August 22, 2006
    Assignee: Gambro, Inc.
    Inventors: Raymond Paul Goodrich, Jr., Dennis Hlavinka
  • Patent number: 7001715
    Abstract: Red blood cells are purified by separating whole blood, such as by centrifugation, to form a red blood cell fraction and a liquid fraction. The whole blood can be defibrinated or treated to prevent coagulation prior to separation. Preferably, the whole blood is bovine blood. The red blood cell fraction is then diafiltered to purify the red blood cells. The purified red blood cells can then be lysed to form a lysate of purified red blood cells. The purified red blood cells and the lysate of purified red blood cells are suitable for use in producing hemoglobin blood substitute.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: February 21, 2006
    Assignee: Biopure Corporation
    Inventors: Robert A. Houtchens, Maria S. Gawryl, William R. Light, Javed Baqai
  • Patent number: 6811778
    Abstract: A method of treatment of a patient includes administering to the patient stored red blood cells and a hemoglobin solution. The stored red blood cells and the hemoglobin solution can be administered to the patient simultaneously. Alternatively, the hemoglobin solution can be administered to the patient prior to administrating the stored red blood cells or the stored red blood cells can be administered to the patient prior to administering the hemoglobin solution. A composition of the invention includes stored red blood cells and a hemoglobin solution.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: November 2, 2004
    Assignee: Biopure Corporation
    Inventors: Thomas C. Page, William R. Light, Edward E. Jacobs, Jr.
  • Patent number: 6653063
    Abstract: A hematology control composition and method of making the composition is provided. The control employs a plurality of components including a synthetic plasma component, a red blood cell component, a platelet component and a leukocyte component. The leukocyte component includes at least one subpopulation having particles derived from other than white blood cells.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: November 25, 2003
    Assignee: Hematronix, Inc.
    Inventors: Frank J. Carver, James D. Lapicola
  • Publication number: 20030165573
    Abstract: Red blood cells are purified by separating whole blood, such as by centrifugation, to form a red blood cell fraction and a liquid fraction. The whole blood can be defibrinated or treated to prevent coagulation prior to separation. Preferably, the whole blood is bovine blood. The red blood cell fraction is then diafiltered to purify the red blood cells. The purified red blood cells can then be lysed to form a lysate of purified red blood cells. The purified red blood cells and the lysate of purified red blood cells are suitable for use in producing hemoglobin blood substitute.
    Type: Application
    Filed: February 28, 2002
    Publication date: September 4, 2003
    Applicant: Biopure Corporation
    Inventors: Robert A. Houtchens, Maria S. Gawryl, William R. Light, Javed Baqai
  • Patent number: 6498141
    Abstract: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: December 24, 2002
    Assignee: Northfield Laboratories, Inc.
    Inventors: Richard E. DeWoskin, Marc D. Doubleday
  • Patent number: 6387353
    Abstract: Dental bleaching compositions are made with a bleaching agent and a stable radiant-energy absorbing compound that acts as a bleaching agent activator. The dental bleaching compositions of the present invention can be one-part, pre-mixed compositions that do not require mixing at the time of treating a patient's teeth but which remain stable over time. The bleaching agent may consist of hydrogen peroxide, either in aqueous form or complexed with urea (carbamide peroxide) or sodium perborate. The bleaching agent activator includes hydrocarbons that are stable in the presence of the bleaching agent, which do not prematurely accelerate liberation of the bleaching agent, but which allow for selective activation of the bleaching agent by irradiation of the bleaching composition with radiant energy.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: May 14, 2002
    Assignee: Ultradent Products, Inc.
    Inventors: Steven D. Jensen, Dan E. Fischer
  • Patent number: 6362003
    Abstract: A method of quality control to diagnose the cause of a malfunction of an instrument. The method uses measurements of the physical property of a sample to diagnose the cause of a malfunction of an instrument. The spatial position of a control product sample is analyzed. Alternatively, the spatial position of a statistically significant number of patient blood samples can be used. The method enables the monitoring of an instrument for problems associated with debris and noise caused by red cell lysis inefficiency; instrument reagents pump volume settings; instrument laser alignments; instrument gain settings; and flow noise caused by partial plugs, residual plugs or other flow problems. The method provides a more specific indication of the type and cause of an instrument malfunctioning than non specific flagging provided by prior art methods.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: March 26, 2002
    Assignee: Coulter Corporation
    Inventors: Carole Young, Michael Elliott, Nancy Naylor, Timothy J. Fischer
  • Publication number: 20020025343
    Abstract: A process is disclosed for the preparation of an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramerfree, substantially stromafree, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.
    Type: Application
    Filed: May 10, 1999
    Publication date: February 28, 2002
    Inventors: RICHARD E. DE WOSKIN, MARC D. DOUBLEDAY
  • Publication number: 20020001624
    Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.
    Type: Application
    Filed: July 12, 1999
    Publication date: January 3, 2002
    Inventors: FRIEDRICH BRAUN, HANS-PETER SPANGLER, JOHANN EIBL
  • Patent number: 6303152
    Abstract: A process is disclosed for the production of immune-genetically active suspensions of which the initial substances are fluids or tissues from the human or animal body. Autohemotherapy, immune-stimulatory and/or immune-suppressive effects are employed. The suspensions thus produced can be used as pooled sera as desired.
    Type: Grant
    Filed: March 15, 1993
    Date of Patent: October 16, 2001
    Inventor: Horst Kief
  • Patent number: 6267925
    Abstract: A system dynamically adjusts the delivery rate of a cryopreservation solution to red blood cells to permit freezing. The delivery rate is preferably determined according to an equation that maintains a linear change of red blood cell osmolarity over time so as to prevent osmolarity shock of the red blood cells. In the preferred embodiment, the system includes a controller that is preconfigured to automatically deliver the cryopreservation solution to the red blood cells in accordance with the equation. The system may also support the recovery of thawed red blood cells by diluting the red blood cells and washing them of the cryopreservative. Again, the system preferably adjusts the delivery rate of a dilution solution so as to prevent osmolarity shock of the red blood cells during the recovery phase. The recovered red blood cells may be suspended in a preservation solution to further increase their shelf-life following the recovery phase.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: July 31, 2001
    Assignee: Haemonetics Corporation
    Inventor: Etienne Pages
  • Patent number: 6231879
    Abstract: This invention is directed to methods of manufacturing implantable biocompatible cell encapsulation devices, wherein the cell encapsulation devices have a jacket made of a permeable, biocompatible material that is loaded with a core made of a reticulate foam scaffold having interconnected pores, with cells that are dispersed in the interconnected pores.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: May 15, 2001
    Assignee: Neurotech S.A.
    Inventors: Rebecca Li, Tyrone F. Hazlett
  • Patent number: 6177106
    Abstract: A method for fractionating red blood cells of human blood into three fractions comprises following steps; (a) human blood sample is mixed with dextran aqueous solution and maintained stationarily for 60 to 75 min to fractionate this blood sample into three layers; (b) the upper, intermediate, and lower layer samples are individually separated and collected; and (c) the upper layer sample is treated with hypotonic solution for a short period and then added with hypertonic solution. Further the invention provides antibacterial or bacterial proliferation inhibitory material produced by the method. This method can easily fractionate three different blood fractions including red blood cells as a main component and having different functions. These three different fractions can be applied to several clinical tests such as antibacterial test and the like.
    Type: Grant
    Filed: August 24, 1998
    Date of Patent: January 23, 2001
    Inventor: Tsukasa Matsumoto
  • Patent number: 6139878
    Abstract: A method using diafiltration to prepare a blood product is described. The method removes contaminating plasma proteins from whole blood or blood products. Diafiltration may be used on paraformaldehyde-fixed platelets to remove formaldehyde to undetectable levels, and to suspend the platelets into a formulation buffer suitable for subsequent treatment, such as lyophilization. The manufacturing procedure can be divided into three steps, a first diafiltration, fixation, preferably with paraformaldehyde, and a second diafiltration. In the first step, plasma proteins are removed from fresh or stored platelets or blood cells. The technique is gentle to prevent the activation and aggregation of the platelets. Fixation stabilizes the platelets to withstand freezing, lyophilization and subsequent reconstitution, and also provides a viral and bacterial reduction.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: October 31, 2000
    Assignee: Aventis Behring, LLC
    Inventors: Louis Summaria, Nathan Roth, Aberash Berhe, Mark Even
  • Patent number: 6117838
    Abstract: A method of treating a mammal suffering from hypotension by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: September 12, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 6114306
    Abstract: Pyruvate kinase deficiency is a blood disease characterized by hemolytic anemia. PCR analysis of cDNA leukocytic extracts of patients with hereditary pyruvate kinase deficiency anemia revealed two overexpressed markers when compared to extracts from healthy individuals. These two markers, proposed as human markers A and B and associated with hereditary hemolytic anemia, have been cloned (HUMDNAMA and HUMDNAMB, Gen Bank Association numbers M64700 and M64701). Our attention has focused on human DNA marker B, a 451 bp open-reading frame. The marker has been cloned in the bacteria vector pGEX-2TK and the expressed protein, called HMF (hemolytic anemia related factor), has been tested for biological activity. It has been observed that the HMF-glutathione transferase fusion protein, added to freshly prepared leukocytes cultures, has an immediate cytotoxic effect and a delayed lymphoblastic effect. The lymphoblastic effect is greatly enhanced when erythrocytes are added to the leucocytes.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: September 5, 2000
    Assignee: Universite de Sherbrooke
    Inventors: Eveline de Medicis, Andre Larochelle
  • Patent number: 6090779
    Abstract: Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: July 18, 2000
    Assignee: Baxter International, Inc.
    Inventors: Robert J. Przybelski, Kenneth E. Burhop
  • Patent number: 6046161
    Abstract: A method for increasing perfusion in a mammal suffering from cardiogenic shock by administering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: April 4, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 6030768
    Abstract: A method diagnosing Alzheimer's disease in a patient includes analyzing conformational changes in a band 3 protein of the patient yielding a time course of the conformational changes. One approach includes analyzing conformational changes in a band 3 protein by measuring band 3 Cl.sup.- /HCO.sub.3.sup.- exchange over time. In this approach a double exponential function is solved for two rate constant estimates by fitting the double exponential function to the time course. At least one of the rate constant estimates is used to determine whether the patient has Alzheimer's disease. A second approach includes analyzing conformational changes in a band 3 protein by measuring the emission spectrum of a stilbene bound to band 3, which emission changes in response to band 3 conformational changes. In this approach, a single exponential function is solved for a parameter by fitting the single exponential function to the time course obtained.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: February 29, 2000
    Assignee: President and Fellows of Harvard College
    Inventors: Frank A. Greco, A. K. Solomon
  • Patent number: 6022850
    Abstract: A method for increasing perfusion in a mammal suffering from stroke by admninistering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: February 8, 2000
    Assignee: Baxter International, Inc.
    Inventor: Robert J. Przybelski
  • Patent number: 5985331
    Abstract: This invention relates to a method for inactivating parasites in blood cell-containing compositions by incubating a mixture of the blood cell-containing composition, a phthalocyanine dye and a quencher and optionally irradiating this mixture with red light. This invention further relates to a method of sterilizing blood cell-containing compositions which contain lipid enveloped viruses and blood borne parasites.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: November 16, 1999
    Assignee: New York Blood Center, Inc.
    Inventors: Paul Gottlieb, Ehud Ben-Hur, Sara Lustigman
  • Patent number: 5981282
    Abstract: Reference controls comprised of aldehyde-fixed white blood cells stabilized red blood cells and simulated blood platelets exhibiting a white blood cell histogram profile that is substantially that of whole blood are obtained by the addition of a lipoprotein to the control and an antioxidant to inhibit lysis of stabilized red blood cells by said lipoprotein.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: November 9, 1999
    Assignee: Streck Laboratories, Inc.
    Inventor: Wayne L. Ryan
  • Patent number: 5948278
    Abstract: A method for enriching rare cell populations from a whole blood sample by separating rare cell fractions from whole blood sample according to the relative charge density and/or the relative binding affinity for a leukocyte depletion solid phase matrix is described. The enrichment method may be operated stand alone, or as a pre or post-processing step in conjunction with a charge-flow separation method.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: September 7, 1999
    Assignee: BioSeparations, Inc.
    Inventors: David W. Sammons, Michael Manley, Joseph G. Utermohlen, Garland E. Twitty
  • Patent number: 5882934
    Abstract: A cyanide-free lytic reagent composition and method for measuring the total hemoglobin concentration in a blood sample, for counting the number of leukocytes and for deferential counting of leukocyte subpopulations are described. The cyanide-free lytic reagent composition cotains a quaternary ammonium salt or a pyridinium salt to lyse erythrocytes and release hemoglobin, and an organic ligand including triazole and its derivatives, tetrazole and its derivatives, alkaline metal salts of oxonic acid, melamine, aniline-2-sulfonic acid, quinaldic acid, 2-amino-1,3,4-thiadiazole, triazine and its derivatives, urazole, DL-pipecolinic acid, isonicotinamide, anthranilonitrile, 6-aza-2-thiothymine, 3-(2-thienyl)acrylic acid, benzoic acid and alkali metal and ammonium salts of benzoic acid, and pyrazine and its derivatives to form a stable chromogen with hemoglobin, and a salt to adjust conductivity of the reagent for impedance measurement.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: March 16, 1999
    Assignee: Coulter International Corp.
    Inventors: Yi Li, Carole Young
  • Patent number: 5883231
    Abstract: There is provided a bodily fluid simulant made from red blood cells in an amount between about 10 and about 60 weight percent, egg white in an amount between 20 and 50 weight percent, and plasma.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: March 16, 1999
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Amy Michele Achter, Crystal Sutphin Leach, Jack Nelson Lindon, Heather Anne Sorebo, Mary Garvie Weber
  • Patent number: 5776914
    Abstract: Disclosed are compositions and methods for preventing or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use of an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: July 7, 1998
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Paul B. Weisz, Edward J. Macarak